BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The recent possibility of undertaking a treatment-free remission (TFR) approach in patients with a stable DMR has underlined the importance of reliable and precise monitoring of BCR–ABL1 molecular levels in CML patients treated with TKIs.